Our achievements in

Read through some of our recent highlights and important findings.

We uncovered the unique set of genes that keeps some cancer cells dormant in our bones. This research may reveal new therapeutic targets for multiple myeloma – a blood cancer that spreads to bone – and other cancers like breast cancer and prostate cancer.

Our scientists discovered that ‘brown’ fat, which burns excess energy as heat, is activated or stopped depending on calories consumed. If we can fine-tune the body’s signal to activate this 'panic switch', excess fat could be burned before it is stored and help stop the obesity crisis.

We developed a way to take genome analysis ‘offline’ or perform it accurately with far less computer memory. This could make it possible to bring genome analysis to hospital bedsides or remote locations.

Our team identified a new structure within the immune system where infections and vaccinations are ‘remembered’. This new ‘micro-organ’ is where the immune cells gather to fight an infection the body has seen before.

Garvan researchers discovered a biomarker in the blood for advanced prostate cancer that can predict whether a patient will respond to chemotherapy.

We established extensive clinical trials programs which use genomic technologies to match patients with many diseases to treatments based on their genetic information. This is fast tracking genomic medicine and precision medicine into the clinic.

Our scientists uncovered the process of a primary breast cancer tumour signalling the immune system to follow the breakaway cells and ‘freeze’ them, thereby stopping secondary tumour growth. It provides insight into new approaches we might use to stop their growth and spread.

Our researchers discovered a critical part of the process of how a genetic variant triggers flares of inflammation in a rare immune disorder: mevalonate kinase deficiency. This could help researchers understand the causes inflammation in other, more common diseases.